Redefining the
pillars of
wound care.
Aceso Plasma is a handheld, portable device that converts ambient air into oxygen plasma — delivering broad-spectrum disinfection, accelerated healing, and hemostasis without chemicals, heat, or the risk of antibiotic resistance.
Investigational device pending FDA clearance · Not for sale
Research validated by
Wound care is broken.
We built a better solution.
Current wound care approaches leave critical gaps — in the clinic, in the operating room, and on the battlefield. Aceso Plasma addresses them all in a single, portable device.
The problems today
Slow healing times. Current treatments fail to accelerate recovery for trauma, burns, and chronic wounds.
Antibiotic resistance. Traditional approaches struggle against drug-resistant ESKAPE pathogens — a growing global crisis.
Chemical disinfectants damage healthy cells. Many standard agents kill bacteria but also impede healing and harm host tissue.
No portable field solution. Existing wound care and decontamination tools are not adapted for austere, mobile, or combat environments.
The Aceso solution
Accelerated healing. ROS disinfection allows the body to bypass the inflammatory stage — reducing healing time by approximately half in investigational studies.
Resistance-free by design. The ROS oxidation mechanism targets all microbial proteins simultaneously — no resistance pathway can develop.
Safe for healthy tissue. Cold plasma operates below 55°C with no chemicals — zero negative impact on healthy host cells observed in investigational studies.
Built for the field. Powered by AC or DC, requires no gas tanks, and operates in any environment — clinical or austere.
Built for clinicians,
military, and investors.
Aceso Plasma addresses critical unmet needs across three distinct communities — each with a compelling case for why this technology matters now.
For clinicians
A new standard for wound care
Cold plasma technology validated at Wake Forest and MedStar Georgetown — effective against antibiotic-resistant ESKAPE pathogens, with no negative impact on healthy tissue. Currently entering FDA clinical trials for chronic wounds.
View the scienceFor military & defense
Designed for the battlefield
Built by Navy SEALs for SOCOM's most demanding environments. Hemostasis, disinfection, and tissue regeneration in a single portable device. SBIR Phase I and II funded. $310K government order fulfilled.
Get in touchFor investors
Investor Relations
Pre-revenue medtech company with $1.55M in SBIR funding, research validated across five independent institutions, and clinical trials beginning at MedStar Georgetown. Experienced founding team with proven exits. Accredited investors welcome to inquire.
Schedule a callResearch-backed.
Independently validated.
Key findings from investigational studies conducted across five independent research institutions.
~50%
Reduction in wound healing time in investigational studies
14+
Pathogen species tested including antibiotic-resistant ESKAPE strains
$1.55M
In SBIR Phase I & II funding awarded by the US Air Force
5
Independent research institutions validating efficacy and safety
All data reflects findings from pre-clinical and investigational research studies. Aceso Plasma is pending FDA clearance and is not currently approved or available for clinical use.
Built by operators.
Validated by scientists.
A team of Navy SEALs, serial entrepreneurs, and world-class researchers with the experience to bring this technology to market.
Zach Steinbock
President
Naval Academy · SEAL Teams · 4x Founder · 2x Exits
Sean Matson
CEO
VMI · SEAL Teams · 4x Founder · 2x Exits
Craig Blanchard
COO
Guidant · NICO Corporation · 25+ Years MedTech
Dr. Spencer Kuo
Chief of Technology
NYU Tandon · 17 DoD/NASA Grants · 40+ Years Research
Dr. Greg Steinbock
CMO
Northwestern · University of Kentucky · Urology Research